Clinical Trials

The purpose of this study is to determine whether impaired insulin-induced suppression of lipolysis (as measured by IC50) is related to lipolysis proteins in groups of volunteers known to vary widely with regards to abdominal adipocyte size and regulation of adipose tissue lipolysis, and whether the improved insulin regulation of lipolysis resulting from treatment with the PPARγ agonist pioglitazone, with or without weight loss, can be linked to specific changes in sets of PPARγ-responsive adipocyte lipolysis proteins in UBO adults.



 

The aim of this study is to develop, in close collaboration with stakeholders, an evidence-based decision aid to inform discussions regarding the treatment of obesity (Obesity Choice).

The aim of the study is to investigate the effects of a 3-month resistance exercise program (in people aged 50 to 75) on muscle mass, body composition, muscle strength, brain function and cognition, muscle efficiency processing blood sugar, the body’s ability to build muscle, and fat cells.

Earlier research has shown that exercise has significant benefits in preventing certain diseases and conditions such as diabetes, dementia, heart disease, and more. We also know from other research that resistance exercise (lifting weights) and aerobic exercise (running, biking, walking), improve metabolism through separate ways on the molecular level, also called “molecular pathways.” With new and sophisticated technologies, we can analyze these molecular pathways to learn how exercise improves health. 

The purpose of the study is to understand why resistance exercise can prevent disease though analyzing the ‘molecular pathways’ in correlation with blood sugar to understand its effects on diabetes. We also will correlate these results with brain scan and cognitive tests to understand the mechanisms behind cognitive decline and dementia. 

Participants in this study will undergo a series of baseline measurements including but not limited to blood tests, brain scans, aerobic exercise tests, body composition scans, resistance exercise, a 24-hour research visit, 4 needle muscle biopsies, 2 needle fat biopsies, and an infusion of amino acids (the building blocks of muscles). 

Following the completion of the baseline visits, participants will be randomly placed into a resistance training group or a control group. 
1.    Resistance Training Group: Participants put into the resistance training program will take part in a personalized resistance training program and meet with a personal trainer four times a week for three months. Following the three months of resistance training participants will repeat the baseline visits and will be completed with the study. 
2.    Control Group: Participants put into the control group are asked not to make any lifestyle changes for 3 months. Following the 3 months, they will come back for a repeat of the baseline measurements. At this point they will have the choice to take part in the resistance training program, followed by a third set of baseline measurements. 

Remuneration is provided. 

Study title: Molecular Mechanisms of Exercise Benefits to Insulin Resistant People
IRB #: 19-006273
Principle Investigator: Dr. K Sreekumaran Nair
 

The purpose of this study is to evaluate the safety and tolerability of 134 days of daily dosing of HU6, to ealuate the effectiveness of HU6 on weight reduction, and  to evaluate the effect of HU6 treatment on exercise capacity.

The objectives of this study are to assess the safety and durability of combined hybrid APC and ESG compared to traditional ESG, and to assess weight loss and improvement in obesity-related co-morbidities in combined hybrid APC and ESG compared to ESG alone.

The purpose of this study is to assess the feasibility of ablation of up to 70% of the gastric mucosa using HybridAPC to induce weight loss.  

The purpose of this study is to evaluate the effectiveness of early time-restricted eating versus, late time restricted eating, and daily caloric restriction alone for obesity, in addition to measure difference in A1c, fasting glucose, and lipid panels. Additionally, we hope to assess barriers to compliance and effect on quality of life.

The purposes of this study are to:  evaluate the feasibility of providing a community based referral to Mayo Clinic ECH patients for weight loss by measuring the number of patients who follow through with the referral, to determine the completion rate of patients enrolled through provider referral to a community based weight loss program, and to determine the level of provider and patient satisfaction with the community based weight loss program process.

The purpose of this study is to prospectively evaluate the safety and effectivenes of standard of care, individualized, comprehensive weight loss interventions in carefully selected patients with obesity undergoing cardiac transplant evaluation, including utilization of best lifestyle modifications and guidance to promote a healthy weight, possible medical therapy using FDA-approved weight loss medications and EBMTs with or without concomitant medical therapy.

The purpose of this study is to demonstrate that the safety of the device in the postmarket setting is comparable to what was observed in the US pivotal study and to more accurately determine the rates of certain serious adverse events so that this information can be used to inform patient labeling.

Subjects in the open label, multi-center study will receive dietary/exercise counseling plus the Spatz3 Adjustable Balloon System for 32 weeks.

Eligible subjects will undergo endoscopy and those without endoscopic contraindications will be implanted with the Spatz3 Adjustable Balloon System for 32 weeks. All subjects will follow a 1000-1200 kcal/day-deficit diet during their participation in the study.

At 18 weeks ±4 weeks, subjects will be evaluated, and those that meet the criteria described below in section 4.3.3.2.4 will undergo an adjustment procedure wherein the balloon volume will be increased to achieve extra weight loss. The balloon adjustment procedure is done with an endoscopy procedure under the same sedation as the implantation procedure.

At the end of the 32-week treatment period, all subjects who lost at least 5% Total Body Weight Loss (TBWL) prior to device removal will be followed for an additional 6 months. In addition, patients with device- and/or procedure-related adverse events will be followed until resolution of the event.